𝔖 Bobbio Scriptorium
✦   LIBER   ✦

1296 DEVELOPING END POINTS FOR CLINICAL TRIALS IN PBC: ALKALINE PHOSPHATASE AS A PREDICTOR OF OUTCOME

✍ Scribed by Meaney, C.; Kumagi, T.; Al-Harthy, N.; Acarsu, U.; Coltescu, C.; Hirschfleld, G.M.

Book ID
122613002
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
42 KB
Volume
54
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The need for levodopa as an end point of
The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and Ξ±-tocopherol
✍ Dr. Peter LeWitt; David Oakes; Lu Cui πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 693 KB

## Abstract Progression of Parkinson's disease (PD) can be detected through changes in clinical ratings or disability assessments. A clinical trial, Deprenyl and Alpha‐Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), used a novel study end point: increase in parkinsonian disability to th